US protection ending in 2037: Infections
As of the edition of 20 October 2026, 9 drugs have US protection that ends in 2037 in infections; 3 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
9 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Baloxavir marboxil | Ends 2037 (patent) | Marketed | Roche | 0 | |
| Clesrovimab | Ends 2037 (computed from the first US licence) | Marketed | Merck & Co. | 0 | |
| Depemokimab | Ends 2037 (computed from the first US licence) | Marketed | GSK | IL5 | 0 |
| Eravacycline | Ends 2037 (patent) | Marketed | L | 0 | |
| Narsoplimab | Ends 2037 (computed from the first US licence) | Marketed | Omeros | MASP2 | 1 |
| Revumenib | Ends 2037 (patent) | Marketed | Syndax Pharmaceuticals | KMT2A, MEN1 | 1 |
| Sars-cov-2 virus spike protein | Ends 2037 (computed from the first US licence) | Marketed | Sanofi | 0 | |
| Zanubrutinib | Ends 2037 (patent) | Marketed | BeiGene | BTK | 1 |
| Zopapogene imadenovec | Ends 2037 (computed from the first US licence) | Marketed | Precigen | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2037 in infections
In the product3 of these 9 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.